ArticleGastro hep advances2026
Prospective Evaluation of Ustekinumab Dose Intensification in Inflammatory Bowel Diseases.
Article in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Backgrounds and Aims: Ustekinumab is an effective therapy for moderate-to-severe inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC). However, secondary loss of response to standard every-8-week maintenance dosing is common. Prospective data supporting dose intensification are limited. To prospectively evaluate the effectiveness and safety of ustekinumab dose intensification to every 4 weeks (q4w) or every 6 weeks (q6w) in patients with IBD experiencing secondary loss of response. Methods: We conducted a prospective cohort study of adults with CD or UC undergoing empiric ustekinumab dose intensification to q4w or q6w. Clinical disease activity was assessed using the Harvey-Bradshaw Index for CD and the Simple Clinical Colitis Activity Index for UC at baseline and following intensified maintenance dosing. The primary outcome was steroid-free clinical remission after the third intensified dose. Secondary outcomes included clinical response, biochemical response using fecal calprotectin, changes in serum ustekinumab concentrations, and adverse events. Results: Nineteen patients (12 CD, 7 UC) were enrolled. After the third intensified dose, steroid-free clinical remission was achieved in 75.0% of CD and 71.4% of UC patients, while over 80% of patients achieved clinical response. Outcomes were similar between q4w and q6w regimens. Serum ustekinumab concentrations increased significantly following dose intensification, whereas biochemical response rates were modest. No new safety signals were observed, and no patients discontinued therapy due to adverse events. Conclusion: Ustekinumab dose intensification to q4w or q6w was safe and associated with improved clinical outcomes in this prospective IBD cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.